Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

J Med Chem. 2015 Dec 24;58(24):9421-37. doi: 10.1021/acs.jmedchem.5b00326.

Ute F Röhrig ¹, Somi Reddy Majjigapu ¹ ², Pierre Vogel ² ³, Vincent Zoete ¹, Olivier Michielin ¹ ³ ⁴

Affiliations

1 Molecular Modeling Group, SIB Swiss Institute of Bioinformatics , CH-1015 Lausanne, Switzerland.
2 Laboratory of Glycochemistry and Asymmetric Synthesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) , CH-1015 Lausanne, Switzerland.
3 Ludwig Center for Cancer Research of the University of Lausanne , CH-1015 Lausanne, Switzerland.
4 Department of Oncology, University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV) , CH-1011 Lausanne, Switzerland.

PMID: 25970480 DOI: 10.1021/acs.jmedchem.5b00326

Abstract

Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for Anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies. Many novel IDO1 Inhibitor scaffolds have been described, and a few potent compounds have entered clinical trials. However, a significant number of the reported compounds contain problematic functional groups, suggesting that Enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1. Here, we describe issues in the employed experimental protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.

Name
Email *

	Sorry, but the email address you supplied was invalid.